Onconic Therapeutics Inc. (476060.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
Onconic Therapeutics Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 14.84 bn KRW | 53.39 bn KRW |
| Gross profit | 14.84 bn KRW | 53.39 bn KRW |
| Operating income | -4.80 bn KRW | 12.62 bn KRW |
| EBIT | -9.28 bn KRW | 13.74 bn KRW |
| Net income | -8.09 bn KRW | 15.78 bn KRW |
| Diluted EPS – continuing operations | -749.04 KRW | 355.12 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Onconic Therapeutics Inc.
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.
More stocks
- Chang Lan Electric Technology Co Ltd (002879.SZ)
- Seers Technology (458870.KQ)
- Citra Putra Realty Tbk PT (CLAY.JK)
- Cham Swiss Properties AG (CHAM.SW)
- BrightSpire Capital, Inc. (BRSP)
- Changzhou Evergreen Technology Co. Ltd. A (001324.SZ)
- IQE PLC (IQE.L)
- Jiangsu Apon Medical Technology Co Ltd Class A (300753.SZ)
- Xinjiang Chalkis Co Ltd (000972.SZ)
- First Bancorp, Inc /ME/ (FNLC)
- CHEMUNG FINANCIAL CORP (CHMG)
- CITIZENS FINANCIAL SERVICES INC (CZFS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.